(Q36624983)

15 August 2017

1 reference

title

Anthracycline cardiotoxicity. (English)

1 reference

15 August 2017

Charles Swanton

2

0 references

author name string

Robin L Jones

series ordinal

1

1 reference

15 August 2017

Michael S Ewer

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Drug Safety

15 August 2017

published in

1 reference

15 August 2017

volume

5

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

791-809

1 reference

A clinicopathologic analysis of adriamycin cardiotoxicity

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Cardiac toxicity of daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Letter: Pericarditis in a case of early daunorubicin cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Acute arrhythmogenicity of doxorubicin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Sudden death during doxorubicin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Adriamycin cardiomyopathy--risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Doxorubicin Cardiomyopathy: Evaluation by Phonocardiography, Endomyocardial Biopsy, and Cardiac Catheterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

The cardiotoxicity of adriamycin and daunomycin in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Adriamycin cardiotoxicity in children.Case reports, literature review, and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Adriamycin and Radiation: Synergistic Cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Anthracycline-induced cardiotoxicity in children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Hyperthermia Potentiates Doxorubicin-Related Cardiotoxic Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Review of tests for monitoring doxorubicin-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Comparison of cardiac function tests after anthracycline therapy in childhood. Implications for screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Cardiac diastolic function in pediatric patients receiving doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Elevated B-type natriuretic peptide levels after anthracycline administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Effect of carvedilol on survival in severe chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Doxorubicin-induced cardiomyopathy treated with carvedilol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Heart transplantation in chemotherapeutic dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

A matter of life and death: cardiac myocyte apoptosis and regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Mitoxantrone: a new anticancer drug with significant clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Bradycardia due to mitoxantrone exacerbated by previous anthracycline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Mitoxantrone-induced bradycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Carnitine promotes heat shock protein synthesis in adriamycin-induced cardiomyopathy in a neonatal rat experimental model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Counteraction of adriamycin-induced oxidative damage in rat heart by selenium dietary supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Prevention of chemotherapy and radiation toxicity with glutamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Does anthracycline administration by infusion in children affect late cardiotoxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Culprit and victim -- DNA topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Liposomal anthracyclines in metastatic breast cancer: clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Use of chemotherapy during human pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Chemotherapy during pregnancy: what is really safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.6.791

21 January 2018

Identifiers

DOI

10.1517/14740338.5.6.791

1 reference

15 August 2017

1 reference